Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06940434 +/- Sasanlimab in Advanced Solid Tumors
NCT04152018Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Nov 2019
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of PF-06940434 in head and neck squamous cell carcinoma (HNSCC), renal cell carcinoma (RCC), ovarian cancer and 8 more (5 arms), sponsored by Pfizer. Primary endpoints: Number of participants with Dose-limiting toxicities, Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities up to 24 months and 6 more. Started Nov 2019; status: terminated.
02
Drugs
PF-06940434
03
Conditions
head and neck squamous cell carcinoma (HNSCC)renal cell carcinoma (RCC)ovarian cancergastric cancer (GC)esophageal cancer
Beyond the preview
Go deeper on NCT04152018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04152018.